Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>The company reported sales of JPY8mn, a 91.5% YoY decline, with an operating loss of JPY374mn.</li><li>Revised FY03/25 forecast shows sales of JPY108mn, R&D expenses of JPY561mn, and a net loss of JPY994mn.</li><li>The company shifted focus to mRNA drug development, enhancing collaborations and launching a contract research business.</li></ul>

The company reported sales of JPY8mn, a 91.5% YoY decline, with an operating loss of JPY374mn.Revised FY03/25 forecast shows sales of JPY108mn, R&D expenses of JPY561mn, and a net loss of JPY994mn.The company shifted focus to mRNA drug development, enhancing collaborations and launching a contract research business.

Nanocarrier (4571 JP): 1H FY03/25 flash update

<ul><li>The company reported no sales in Q2 FY03/23, with operating and recurring losses narrowing YoY due to decreased SG&A expenses.</li><li>The company shifted its focus to mRNA drug candidates and IP licensing, enhancing collaborations and research progress.</li><li>The company ended its fertility treatment support business in May 2024 and ceased sales of Depth products in December 2022.</li></ul>

The company reported no sales in Q2 FY03/23, with operating and recurring losses narrowing YoY due to decreased SG&A expenses.The company shifted its focus to mRNA drug candidates and IP licensing, enhancing collaborations and research progress.The company ended its fertility treatment support business in May 2024 and ceased sales of Depth products in December 2022.

Nanocarrier (4571 JP): Q1 FY03/25 flash update

Japan

NanoCarrier Co., Ltd. is a biotech company that utilizes micellar nanoparticle (polymeric micelles) technology for the production and development of pharmaceuticals focusing mainly on cancer therapies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nanocarrier (4571 JP)